Filtered By:
Specialty: Consumer Health News
Drug: Pradaxa
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 21 results found since Jan 2013.
Special MRI scan could identify stroke risk in people with atrial fibrillation
Atrial fibrillation is a heart rhythm disorder that affects millions of people. It can make you feel lousy. Even worse, it can cause potentially disabling or deadly strokes. A special MRI scan may — I stress the “may” — help identify people with atrial fibrillation who are at high risk of having a stroke. This could help many people with this condition to avoid taking warfarin or other clot-preventing medications for life.
A normal heartbeat starts in a cluster of cells called the pacemaker. It sits in the heart’s upper right chamber (the right atrium). These cells generate a pulse of electricity that...
Source: New Harvard Health Information - April 28, 2015 Category: Consumer Health News Authors: Howard LeWine, M.D. Tags: Heart Health atrial fibrillation MRI prevention special MRI scan Stroke Stroke Risk Source Type: news
Reversing the effects of the new anti-clotting drugs
The oral anticoagulant warfarin (Coumadin) became available for prescription in 1954. This anti-clotting drug commanded national attention when President Dwight Eisenhower received the drug as part of his treatment following a heart attack. No other oral anticoagulant was successfully developed and marketed in the United States until 2010.
Warfarin is a dangerous drug. Along with insulin, it is responsible for the most emergency hospitalizations due to adverse drug reactions. Whereas insulin causes low blood sugar, warfarin is notorious for the complication of major bleeding. Warfarin is plagued by hundreds of drug-drug an...
Source: New Harvard Health Information - December 9, 2015 Category: Consumer Health News Authors: Samuel Z. Goldhaber, MD Tags: Drugs and Supplements Health Heart Health Hypertension and Stroke anti-clotting coumadin deep-vein-thrombosis DVT Source Type: news
Pradaxa Fails to Prevent Recurrence After Cryptogenic Stroke Pradaxa Fails to Prevent Recurrence After Cryptogenic Stroke
Dabigatran, sold under the brand name Pradaxa by Boehringer Ingelheim to prevent stroke in people with atrial fibrillation, is no more effective than aspirin for preventing a subsequent stroke in patients who have experienced a cryptogenic stroke.Reuters Health Information
Source: Medscape Medical News Headlines - May 16, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news
Remember to weigh up risks and benefits of new PBS-listed anticoagulants
NPS MedicineWise is reiterating safety messages around the newer anticoagulants dabigatran (Pradaxa) and apixaban (Eliquis) following their PBS listing for preventing stroke on 1 September 2013 - and again for rivaxabaran (Xarelto) which was PBS listed in August for the same purpose. These medicines will be subsidised by the Pharmaceutical Benefits Scheme (PBS) for preventing stroke in people with non-valvular atrial fibrillation, and may offer alternatives for some people...
Source: Health News from Medical News Today - September 4, 2013 Category: Consumer Health News Tags: Stroke Source Type: news
Dabigatran Concentrations and Ischemic Stroke in AFDabigatran Concentrations and Ischemic Stroke in AF
Learn more on how ischemic stroke and bleeding outcomes are tied to dabigatran plasma concentrations. Journal of the American College of Cardiology
Source: Medscape Today Headlines - March 6, 2014 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Dabigatran Etexilate for Secondary Stroke PreventionDabigatran Etexilate for Secondary Stroke Prevention
While dabigatran has proven effective for reducing stroke risk in patients with nonvalvular atrial fibrillation, there is growing concern regarding potential adverse effects. What are the risks? Therapeutic Advances in Neurological Disorders
Source: Medscape Today Headlines - June 13, 2014 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
Thrombolysis for Ischemic Stroke After Reversal of Dabigatran Thrombolysis for Ischemic Stroke After Reversal of Dabigatran
Is idarucizumab administration safe and effective in patients with AF treated with dabigatran who develop acute ischemic stroke requiring thrombolysis?Journal of Medical Case Reports
Source: Medscape Today Headlines - October 9, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
rt-PA in Ischemic Stroke After Idarucizumab Administration rt-PA in Ischemic Stroke After Idarucizumab Administration
This case demonstrates that thrombolytic therapy with rt-PA after reversal of dabigatran with idarucizumab may be safe and feasible in patients with acute ischemic stroke with lacunar infarct.Journal of Medical Case Reports
Source: Medscape Today Headlines - February 4, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
Will new pill to stop a clot save me from a stroke?
I have recently been prescribed Pradaxa to prevent clots and have been told there is a 3 per cent chance of me having a stroke. Is this a high risk, asks Lionel Jenkins, New Zealand
Source: the Mail online | Health - December 18, 2017 Category: Consumer Health News Source Type: news
An Aspirin a Day: Is the Benefit Worth the Risk?
Studies have shown that aspirin, the age old remedy for pain and fever, also thins the blood. Because of this property, it can also help to lower the chances of a heart attack or a stroke caused by a blood clot in the brain. And, although research has found that it only works in certain people (specifically, those with a history of heart attack or stroke) many Americans are inappropriately taking daily, low doses of aspirin as a preventative measure. In fact, researchers have found that about 12 percent of the of nearly 69,000 U.S. adults taking aspirin on a long-term basis should not have received the prescription in the ...
Source: Healthy Living - The Huffington Post - March 13, 2015 Category: Consumer Health News Source Type: news
Early-Phase NOAC, VKA Therapy: Similar Bleeding, Stroke Risk Early-Phase NOAC, VKA Therapy: Similar Bleeding, Stroke Risk
Thus, physicians must be just as cautious when initiating dabigatran or rivaroxaban as when initiating a vitamin-K agonist, the authors of this French nationwide cohort study say. Heartwire from Medscape
Source: Medscape Medical News Headlines - August 6, 2015 Category: Consumer Health News Tags: Cardiology News Source Type: news
Real-world Study Reassures on Dabigatran Stroke, ICH Rates Real-world Study Reassures on Dabigatran Stroke, ICH Rates
But results confirm gastrointestinal bleeding risk, particularly in the elderly and those with renal failure, and questions over the MI risk still remain.Medscape Medical News
Source: Medscape Medical News Headlines - November 29, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Weigh Risks And Benefits Of Old And New Oral Anticoagulants
NPS MedicineWise is urging health professionals to weigh the risks and benefits of oral anticoagulant therapies in people with non-valvular atrial fibulation (AF) following the Pharmaceutical Benefits Advisory Committee (PBAC) recommendation that newer oral anticoagulants (NOACs) be listed on the Pharmaceutical Benefits Scheme (PBS). Following an extensive review of NOACs over the past two years, PBAC has now recommended that dabigatran (Praxada), rivaroxaban (Xarelto), and apixaban (Eliquis) be subsidised under the scheme for stroke prevention in non-valvular AF...
Source: Health News from Medical News Today - May 1, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news
Dabigatran 'Real Life' Results Suggest Caution NeededDabigatran 'Real Life' Results Suggest Caution Needed
New data from real-life experience of dabigatran for stroke prevention in AF show that it is often used outside prescribing recommendations, and the risk for both thromboembolism and bleeding may be raised in patients switched from warfarin. Medscape Medical News
Source: Medscape Today Headlines - May 15, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Stroke Prevention in Patients With Mechanical Heart ValvesStroke Prevention in Patients With Mechanical Heart Valves
Dr. Hans-Christoph Diener discusses the RE-ALIGN trial comparing dabigatran vs warfarin in patients with mechanical heart valves. Medscape Neurology
Source: Medscape Today Headlines - October 28, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery Commentary Source Type: news
